Glaukos (NYSE:GKOS) Price Target Raised to $234.00

01 Nov 2026, 06:13 by Kim Johansen · The Markets Daily

Glaukos (NYSE:GKOS – Free Report) had its price objective lifted by BTIG Research from $205.00 to $234.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

GKOS has been the subject of a number of other research reports. UBS Group assumed coverage on shares of Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price objective for the company. Piper Sandler reissued an “overweight” rating and issued a $240.00 target price (up from $195.00) on shares of Glaukos in a research report on Thursday. Citigroup raised their target price on shares of Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Stifel Nicolaus boosted their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Wells Fargo & Company upped their price target on shares of Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $216.71.

Get Our Latest Research Report on Glaukos

Glaukos Stock Performance

Glaukos stock opened at $236.92 on Thursday. The firm has a market capitalization of $14.03 billion, a P/E ratio of -80.58 and a beta of 0.69. The stock has a fifty day moving average price of $173.30 and a 200 day moving average price of $141.14. Glaukos has a 52 week low of $80.90 and a 52 week high of $248.75. The company has a current ratio of 4.57, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS – Get Free Report) last released its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The firm had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. During the same period in the prior year, the business posted ($0.16) earnings per share. The firm’s revenue for the quarter was up 58.0% compared to the same quarter last year. Equities research analysts anticipate that Glaukos will post 0.15 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at $7,107,140. This trade represents a 6.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 20,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total value of $3,602,600.00. Following the completion of the transaction, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 82,500 shares of company stock valued at $14,862,000. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Glaukos

A number of institutional investors have recently modified their holdings of the company. State of Wyoming raised its holdings in Glaukos by 6.8% in the third quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock valued at $169,000 after buying an additional 66 shares during the period. Wealth Alliance LLC lifted its position in Glaukos by 4.5% during the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after buying an additional 98 shares in the last quarter. Abel Hall LLC grew its stake in Glaukos by 3.5% during the third quarter. Abel Hall LLC now owns 3,236 shares of the medical instruments supplier’s stock worth $531,000 after buying an additional 108 shares during the period. Choreo LLC grew its stake in Glaukos by 4.0% during the third quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier’s stock worth $582,000 after buying an additional 136 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Glaukos by 25.4% during the third quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 138 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

Positive Sentiment: Glaukos reported third-quarter revenue of approximately $211 million, up 58% year over year and well above the $168 million analyst consensus. Earnings were $0.47 per share versus expectations for a $0.10–$0.12 loss and a $0.16 loss in the prior-year quarter. Glaukos Q3 earnings and revenues surpass estimates
Positive Sentiment: Management raised fiscal 2026 revenue guidance to $775 million–$785 million, substantially above the roughly $691.5 million consensus estimate. It also set a preliminary fiscal 2027 sales target of $1 billion, versus Wall Street expectations of about $849 million, reinforcing the growth story. Glaukos sets $1 billion 2027 sales goal
Positive Sentiment: Analyst sentiment improved following the results. Zacks Research upgraded GKOS from “hold” to “strong buy,” while Needham raised its price target to $251 and JPMorgan lifted its target to $240, maintaining an “overweight” rating.
Neutral Sentiment: Other firms also raised their targets, including Wells Fargo to $226, BTIG to $234 and Stifel to $225. However, each remains below the recent trading level, suggesting analysts are becoming more constructive while still seeing limited near-term upside at the current valuation.
Negative Sentiment: The headline profit included factors that may not fully reflect recurring operating earnings. Glaukos continues to report a negative net margin, and commentary noted that underlying profitability is thinner than adjusted figures suggest. With a price-to-earnings ratio based on losses and the stock near its 52-week high, expectations and valuation remain elevated.

About Glaukos

(Get Free Report)

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.